Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Abstract: This invention relates to bio synthesis of novel nano gold through environment friendly process with the aid of plant materials classified under the taxonomical genus Dalbergia, Citrus, Ferula and Dolichos or Macrotyloma. The present inventive product novel nano gold finds utility in, the treatment of humans and animals, nutraceutical, cosmeceutical and herbal composition, the field of technology including but not limited to nano technology, green technology and bio technology. The invention also relates to the use of plant materials in the purification and particle size reduction of metals.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: A dispenser for an animal attractant including: a housing, wherein the housing includes a chamber for containing a spool; a spool, wherein the spool is associated with the chamber of the housing, and wherein the spool is associated with a deer attractant; and wherein the deer attractant includes a substrate, wherein the substrate is associated with an agent wherein the agent includes a deer attractant.

Abstract: A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular androstane and pregnane steroids, and comparable non-conjugated compounds.

Abstract: Discloses a novel synergistic herbal composition comprising combination of therapeutically effective amount of Vrun bhavit, Kadalikshar, Apamargkshar, Yavkshar and optionally Gomutrakshar along with pharmaceutical acceptable additives, useful for the treatment of kidney stone and other urinary disorders like inflammation and urinary stent related problems.

Abstract: A device for rotating at least one mandrel coupled to a secondary reduction gear that can in turn be coupled to a primary reduction gear and supplies a torque to the mandrel. The primary reduction gear is driven by at least one driving motor, the primary and secondary reduction gears are mechanically similar and can be coupled via at least one torque transmission means rotated by the primary reduction gear along a rotation axis, the torque transmission means includes at least one coupling tube with two section ends. Furthermore, in the assembled configuration, the primary and secondary reduction gears define a unitary assembly integrally encapsulating the torque transmission means that can be removed from the unitary assembly in the permanent assembled configuration through an opening of the unitary assembly formed in at least one of the walls of the primary and secondary reduction gears opposite the section ends of the torque transmission means.

Abstract: A growing medium for use in plugging pest orifices includes a bulking agent and a water-retentive polymer blended together and compressed at a volume-to-volume ratio greater than 3:1, wherein the growing medium is at least 50% superabsorbing polymer.

Abstract: A process in which urine is optionally filtered to remove solid extraneous matter and optionally treated so as to reduce the phenolic content of the urine to give and the resulting fluid is then subjected to a solid extraction of the major concentration steroids content therefrom by a first suitable resin (to yield a first resin laden with major concentration steroids and a minor concentration steroid laden first liquid remainder). The minor concentration steroid liquid remainder is subjected to a solid extraction of the minor concentration steroid content therefrom by a second suitable resin (to yield a second resin laden with minor concentration steroids and a second liquid remainder). The first and second resins laden with their respective steroids are then eluted and the eluates are collected separately and optionally subjected to further purification and chromatographic separations, with each resulting separate collection being analyzed for the steroid content thereof.

Abstract: Deicing products designed to deter ungulates are provided, along with methods of using those products to treat iced surfaces. The deicing product comprises a mixture of a deicer along with an ungulate repellent. The repellent can repel based on conditioned avoidance, fear, chemical irritation, and/or bad taste. The deicer can be a salt or a deicer solution. The invention is useful for deterring any ungulate that might be attracted to a component of the deicing product (e.g., the salt), but it is particularly useful for deterring deer.

Abstract: Time release repellent formulations and methods of making formulations, comprising a natural repellent, alum in an amount effective to keep microbial count below a pre-determined level and a natural binder. The natural repellent may be animal urine or a natural oil. The natural binder is selected from the group consisting of: rice, pearlite, polymer, peat moss, clay and foam. The pH level of the formulation is maintained within a pre-determined range by adding a natural acid to lower the pH level or adding a natural base to raise the pH level.

Abstract: The present invention provides devices and methods for concentrating a fluid and for treating a patient with the concentrated fluid. The concentrator apparatus includes a main housing (12) defining a separation chamber (14), a filter housing (48) containing a filter (46) comprising a filter element, a piping (44) for moving concentrated fluid from the separation chamber to the filter, and ports (32) for pressurizing the concentrated fluid past the filter element of the filter. The present invention also provides a variety of uses of concentrated body fluids, including autologous concentrated body fluid. The concentrated fluids can be used for example in surgical applications, including graft applications such as allograft, xenograft and autograft applications.

Abstract: A novel bio platinum complex which increases the therapeutic applicability and effectiveness of platinum used as a cancer treatment in humans and animals especially in anti tumor treatments and to prevent the spread of cancer without fear of high toxicity. The present invention provides for a new method of administration of the bio platinum complex, which is oral administration in specific dosage with suitable carriers either by itself or in combination with other metals or minerals. The administration of the novel bio platinum complex can be carried out in combination with other plant materials depending on the nature of the treatment afforded. Use of the novel bio Platinum complex extends to agriculture and horticulture. Further, the invention is characterized by the irreversible nature of the bio platinum to its metallic form, high solubility, and the non-toxic nature when used in specific dosage, which increases the utility of platinum, in various other fields apart from its therapeutic applications.

Abstract: The present invention relates to use of Ulinastatin and its pharmaceutical composition for treating and/or preventing Severe Acute Respiratory Syndrome (SARS). Ulinastatin is effective for treating and/or preventing SARS, particularly Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Ulinastatin is generally used as the pharmaceutical composition, preferably in the form of freeze-dried powder or aqueous solution for injection.

Abstract: The present invention relates to a synergistic composition useful as plant and soil health enhancer, comprising urine, neem and garlic, individually or in all possible combinations, with the treatment showing it has the ability to stimulate accumulation of nutrients in the plant biomass, proliferation of plant growth promoting, phosphate solubilizing, abiotic stress tolerant and antagonists towards plant pathogenic fungi, control phytopathogenic fungi in the rhizosphere of plants, and enhances the total phenolic contents of the plants.

Abstract: The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

Abstract: A synthetic urine solution and method of its manufacture are disclosed. The solution includes water having a pH between 3 and 10. The solution further includes creatinine and means for removing bacteria from the solution so as to control or eliminate sepsis of the urine solution, preferably through the use of biocide. The solution exhibits a specific gravity of from 1.005 g/cm3 to 1.025 g/cm3. Additional compounds may also be included to further enhance the aesthetics or apparent authenticity of the synthetic urine produced according to this invention.

Abstract: The present invention is a lure optimized for a particular animal such as deer. The optimized lure is made using urine from only two animals urinating at approximately the same time. The animals can be either male or female, but preferably, females in estrus are used for optimal results. This mixture of urine is not diluted in any manner with that of additional animals or preservatives. The urine for the lure is obtained by using a single stall exclusively for only two animals for the purpose of gathering urine. This technique has been especially effective in attracting wandering bucks in rut.

Abstract: A means for following the growth of experimental neoplasms involves administering recombinant tumor cells containing an expression construct encoding a secretable marker to an experimental animal and measuring secreted marker in the urine of animals bearing tumors formed by such recombinant tumor cells. Urinary marker levels are quantitatively related to tumor loads. Urinary marker can be detected before tumors are grossly visible or clinically apparent. Marker levels decrease following surgical excision or chemotherapeutic treatment, with an estimated half-life of 11 hours. This approach is applicable to the study of many experimental tumor systems.

Abstract: The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

Abstract: The invention is basically an animal attractant that is made from human urine and animal urine. The attractant consists of a mixture of 14 to 15 parts male human urine 1 to 2 parts animal urine. The human urine is aged for two to three days. In the preferred embodiment the invention is a deer attractant. The attractant is a mixture of 14 to 15 parts human urine and 1 to 2 part deer urine. The human urine could be male, female or female during menstruation human urine. The deer urine can be doe urine, doe urine in estrous, or buck urine, both natural and synthetic. From experiments done by the inventor he found that male human urine mixed with synthetic buck urine worked best.

Abstract: The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

Abstract: The present invention relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity. The present invention further relates to pharmaceutical compositions comprising such fractions for treating the effects of HIV infection.

Abstract: The present invention relates to an efficient process of vermicomposting and production of high-quality vermicompost from agro-waste(including distillation waste) using animal urine such as cattle urine.

Abstract: The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

Abstract: A viscous, non-liquid, non-gel scent lure for hunting, consisting of animal urine and a thickening agent. The thickening agent may comprise about 1% to about 7% by weight. The resulting viscosity of the solution ranges from about 1500 to about 10,000 centipoise.

Abstract: The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain as well as methods of promoting hematopoiesis, using human chorionic gonadotropin, employing the &bgr;-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or perparations of human chorionic gonadotropin, such as fractions of humna early pregnancy urine, which fractions have pro-hematopoietic activity. The present invention further relates to pharmaceutical compositions for promoting hematopoiesis.

Abstract: The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity, anti-cancer activity, and/or pro-hematopoietic activity. The present invention further relates to pharmaceutical compositions for treating and/or preventing HIV infection, cancer, and/or for promoting hematopoiesis.

Abstract: A method for chemical modification of mammal urine and mammal blood is disclosed.

Abstract: A method for luring animals, repelling animals and training animals and a product used therewith comprising microporous beads having animal attractant scents, animal repellant scents and animal training scents, respectively, imbibed within the beads. The beads with the animal attractant scents are configured to release the animal attractant scents in order to attract a predetermined animal. Likewise, the beads with the animal repellant scents are configured to release the animal repellant scents in order to repel a predetermined animal. Similarly, the beads with the animal training scents are placed onto a predetermined location and a predetermined animal is trained to perform a predetermined sequence using the beads.

Abstract: The invention relates to a novel pharmaceutical composition comprising an effective amount of bio-active fraction from cow urine distillate as a bioavailability facilitator and pharmaceutically acceptable additives selected from anticancer compounds, antibiotics, drugs, therapeutic and nutraceutic agents, ions and similar molecules which are targeted to the living systems.

Abstract: A method and system are provided for preserving nucleic acids in a bodily fluid, such as urine, blood, blood serum, and amniotic fluid. The preservative includes an amount of a divalent metal chelator selected from ethylenediaminetetraacetic acid (EDTA), [ethylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA) and 1,2-bis(2-aminophenoxy)ethane-N,N,N′, N′-tetraacetic acid (BAPTA), or salts thereof in the range of from about 0.001M to 0.1M; and an amount of at least one chelator enhancing component selected from lithium chloride, guanidine, sodium salicylate, sodium perchlorate, and sodium thiocyanate in the range of from about 0.1M to 2M.

Abstract: A method for chemical modification of mammal urine and mammal blood is disclosed.

Abstract: A process is disclosed for the production of immune-genetically active suspensions of which the initial substances are fluids or tissues from the human or animal body. Autohemotherapy, immune-stimulatory and/or immune-suppressive effects are employed. The suspensions thus produced can be used as pooled sera as desired.

Abstract: A method for chemical modification of mammal urine and mammal blood is disclosed.

Abstract: A proteoglycan (“azaftig”) with a molecular weight of approximately 24,000 Dalton has been isolated and partially characterized from the urine of cachectic cancer and non-cancer patients. Azaftig has been shown to bind to receptors on fat cell membranes, and to cause lipolysis. Azaftig does not bind to muscle cell membranes, or cause proteolysis in muscle tissue. Azaftig detection in urine or other body fluids will allow early identification of patients in which weight loss may become a problem. Azaftig may also aid fat loss in humans in which obesity is a threat to health.

Abstract: The simulation of mammalian male reproductive secretions or seminal fluids by specific odoriferous chemical compounds comprised of 1-Methyl Pyrrolidine, 1-Methyl-2-Pyrrolidine Methanol, 1-Methyl-2 Pyrrolidine Ethanol, Pyrrolidine and 2-Pyrrolidone either alone or in various combinations with one another. The simulated seminal fluid's novel odor and appearance is enhanced by the incorporation of various thickeners, suspending agents, solvents, coloring agents, preservatives and surfactants.

Abstract: The present invention relates to animal scent attractants. More particularly, the present invention relates to a composition of matter for amplifying and preserving animal scents. Fox urine, coyote urine, deer urine, elk urine, moose urine, bear urine, rabbit urine, fish oils, and sheep manure are examples of substances which can be used with the present invention.

Abstract: A human glycyrrhetinic-acid-like factor which inhibits certain enzymes in pathways of steroid hormone degradation is disclosed.

Abstract: A semi-solid deer attractant lure comprised of liquid deer urine plus a sufficient amount of flavorless gelatin to produce a semi-solid rubbery composition is disclosed. Also disclosed is a method of making and a method of using the deer attractant lure composition.

Abstract: The present invention is directed to a soluble thrombomodulin-containing composition comprising at least one molecular species of soluble thrombomodulin, and at least one member selected from the group consisting of maltose, lactose, sucrose, arginine and a salt thereof, and a nonionic surface-active agent; and a production method therefor; as well as a stabilizing agent; a stabilization method; an anti-adsorption agent; and an anti-adsorption method for the soluble thrombomodulin. The present invention provides a soluble thrombomodulin-containing lyophilized preparation which is useful as a prophylactic or therapeutic agent for diseases associated with abnormalities in blood coagulation, and which is stable for a prolonged period of time and would not become adsorbed onto the container; and a production method therefor; as well as a stabilization agent; a stabilization method; an anti-adsorption agent; and an anti-adsorption method for the soluble thrombomodulin.

Abstract: Ulinastatin-containing suppository is produced by emulsifying an aqueous solution of ulinastatin in an oily base uniformly in the presence of an emulsifier and then solidifying the emulsion.The ulinastatin-containing suppository exhibits high stability even if it is stored for a prolonged time. In addition, it can be manufactured on an industrial scale.

Abstract: A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in protection of meals against viral infections.

Abstract: A non-toxic rodent deterrent made from dried fecal matter and/or dried urine from mammals of the Mustelidae Family (e.g. weasels, ferrets, minks, martens, etc.). The rodent deterrent material may be used in its bulk from or this material may be placed in a container for either interior or exterior use.

Abstract: Autocrine growth factors and isoforms of those factors have been identified, isolated, purified and manipulated. Nucleic acid segments coding for the factors, and antibodies directed to the factors are also aspects of the present invention. The effect of these growth factors on cells is to enhance their growth by increasing mitogenesis. In particular, the growth factors stimulate kidney epithelial cell growth. The growth factors differ from others previously reported in their molecular weights and other properties, for example, resistance to denaturation by dithiothreitol. Methods of preparation and use of the factors are also described. The growth factors are released from kidney epithelial cells by short exposures to a low-sodium environment. The factors have potential for treatment of kidney disease.

Abstract: A lymphokine is taught which can be used to activate and stimulate CD3.sup.+, CD4.sup.+ T cells, as well as Sezary leukemic T cells. The lymphokine can be obtained from mitogen-stimulated peripheral blood mononuclear cells or urine of Sezary Syndrome patients. The lymphokine upregulates interleukin-2 receptors.

Abstract: A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.

Abstract: A highly purified, Na.sup.+,K.sup.+ -ATPase inhibitory factor is disclosed herein. The factor does not cross-react with anti-digoxin antibody and exhibits uniquely characteristic UV absorbance maxima at approximately 202-210 nm and at 274-280 nm. The inhibitory factor has a molecular weight of less than 1000 Daltons, is non-peptidic, non-lipidic, and loses activity following charring or alkaline hydrolysis. The factor is useful as a pharmaceutical composition in methods for treating essential hypertension, cardiac malfunction and in regulating angiogenesis and active sodium transport and other conditions. Methods for purifying the factor from tissue and fluid extracts are also disclosed.

Abstract: The present invention provides methods for treating Parkinson's disease by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of urine peptide fractions containing 3-[N-phenylacetylaminopiperidine]-2,6-dion.

Abstract: A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.